{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:54:45Z","timestamp":1782528885200,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this study was to evaluate human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) in ovarian clear cell carcinoma (OCCC) by using two antibodies and two scoring guidelines in correlation with <jats:italic>HER2<\/jats:italic> amplification and clinicopathological features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>A tissue microarray was constructed by use of a total of 71 OCCC cases for IHC (the A0485 antibody and the 4B5 antibody) and dual\u2010colour silver <jats:italic>in\u2010situ<\/jats:italic> hybridisation (DISH). Two pathologists independently scored the IHC according to the 2018 American Society of Clinical Oncology (ASCO)\/College of American Pathologists (CAP) breast cancer guidelines (breast guidelines) and the 2016 ASCO\/CAP gastro\u2010oesophageal adenocarcinoma guidelines (gastric guidelines). IHC concordances between A0485 and 4B5 were 87.3\u201393.0%. Three to 16 (4.2\u201322.5%) cases had an IHC score of 2+\/3+ with frequent basolateral\/lateral membranous staining. The 4B5 antibody yielded fewer IHC 2+ cases than the A0485 antibody (<jats:italic>n<\/jats:italic>\u00a0=\u00a02\u20136 versus <jats:italic>n<\/jats:italic>\u00a0=\u00a05\u201312). Five (7.0%) cases had <jats:italic>HER2<\/jats:italic> amplification as determined with DISH. Cases with papillary\u2010predominant growth patterns were significantly more likely to have <jats:italic>HER2<\/jats:italic> amplification (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.0051). In predicting DISH results, IHC scored according to the gastric guidelines yielded 100%\/100% sensitivity and 83.3\u201395.5%\/98.2\u2013100% specificity, and IHC scored according to the breast guidelines yielded 60\u201380%\/33.3\u201366.7% sensitivity and 95.5\u2013100%\/100% specificity (including\/excluding IHC 2+ cases). One case had intratumoral heterogeneity, with discordant results between primary and metastatic tumour specimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We demonstrated <jats:italic>HER2<\/jats:italic> amplification in 7% of OCCC cases, and the molecular change is significantly associated with papillary\u2010predominant growth patterns. In predicting <jats:italic>HER2<\/jats:italic> amplification, a combination of 4B5 IHC and gastric guidelines provides the best sensitivity and fewer equivocal (IHC 2+) cases. Given the intratumoral heterogeneity, assessment of HER2 status on whole tissue sections and on both primary and metastatic tumour specimens is recommended.<\/jats:p><\/jats:sec>","DOI":"10.1111\/his.14419","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T08:35:48Z","timestamp":1622018148000},"page":"758-767","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma"],"prefix":"10.1111","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-2543","authenticated-orcid":false,"given":"Shih\u2010Yao","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeh\u2010Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology Heping Fuyou Branch Taipei City Hospital Taipei Taiwan"},{"name":"College of Nursing National Taipei University of Nursing and Health Sciences Taipei Taiwan"},{"name":"Institute of Public Health National Yang Ming Chiao Tung University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-4291","authenticated-orcid":false,"given":"Chih\u2010Yi","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital Taipei Taiwan"},{"name":"College of Nursing National Taipei University of Nursing and Health Sciences Taipei Taiwan"},{"name":"School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology Taipei Veterans General Hospital Taipei Taiwan"},{"name":"Institute of Clinical Medicine National Yang Ming Chiao Tung University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung\u2010Ru","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital Taipei Taiwan"},{"name":"School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-2784","authenticated-orcid":false,"given":"Jen\u2010Fan","family":"Hang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Taipei Veterans General Hospital Taipei Taiwan"},{"name":"School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Female genital tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.243"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194993"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31819c4271"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.12.024"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60028-2"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0331-CP"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.65"},{"key":"e_1_2_8_12_1","unstructured":"Nordic Immunohistochemical Quality Control.Assessment Run B29 2020 HER2 IHC.2020[Accessed February 5 2021]. Available at:https:\/\/www.nordiqc.org\/downloads\/assessments\/132_11.pdf."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2002.tb01231.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.05.055"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.2003.13028.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13704"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1688"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-016-0553-8"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2011-200082"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000677"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2011-200616"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0304-9"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0268-3"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.043"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-433"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0207-RA"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.198"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6693"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-201647"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e3283513e8b"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31814fa9b0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy166"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.422"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.05.009"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.113"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2000.5837"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001138"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.104"},{"key":"e_1_2_8_39_1","first-page":"1483","article-title":"Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial","volume":"22","author":"Lheureux S","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00333"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.14419","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/his.14419","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.14419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T23:32:34Z","timestamp":1693351954000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.14419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/his.14419"],"URL":"https:\/\/doi.org\/10.1111\/his.14419","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"2021-04-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}